GENOME SEQUENCES





Complete Genome Sequence of *Pseudomonas aeruginosa* Bacteriophage PASA16, Used in Multiple Phage Therapy Treatments Globally

Sivan Alkalay-Oren,^a Ortal Yerushalmy,^a Karen Adler,^a Leron Khalifa,^a Daniel Gelman,^a Shunit Coppenhagen-Glazer,^a Ran Nir-Paz,^b [®]Ronen Hazan^a

^aInstitute of Biomedical and Oral Research (IBOR), Faculty of Dental Medicine, Hebrew University of Jerusalem, Israel ^bDepartment of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center Jerusalem, Israel

Sivan Alkalay-Oren and Ortal Yerushalmy contributed equally to this work. Author order was determined based on seniority.

ABSTRACT PASA16 is a *Pseudomonas aeruginosa* phage isolated from a soil sample and used to treat several patients suffering from persistent infections in various countries. PASA16's genome was sequenced, analyzed, and deposited in GenBank.

P seudomonas aeruginosa is an opportunistic pathogen which commonly causes infections in health care settings (1–3). Its antibiotic-resistant strains are among the most challenging to treat and reportedly cause 32,600 infections yearly and 2,700 deaths in hospitalized U.S. patients (4).

Phage therapy is currently one of the most promising solutions to the emergence of antibiotic-resistant bacteria in general and against *P. aeruginosa* in particular.

Here, we report the genome sequence of the anti-*P. aeruginosa* phage PASA16, used in several phage-therapy treatments (5). PASA16 was isolated in Jerusalem from a garden (31°45′42″N, 35°10′19″E) soil sample and purified using the phage titration method (6, 7). Briefly, the sample was dissolved in LB and mixed with overnight-grown *P. aeruginosa* PA14 at 37°C. The culture was centrifuged (7,100 × *g*, 10 min), and the supernatant was filtered (0.22 μ m). Serial dilutions of 5 μ L of the filtrate were spotted on *P. aeruginosa* PA14 lawn, and after overnight incubation at 37°C, the clearest plaques were picked, and their titer was determined. The phage particles were visualized by transmission electron microscopy (TEM) (Fig. 1) as described (6).

DNA was purified (phage DNA isolation kit; Norgen Biotek) from a single plaque that was picked and grown to a titer of 10⁹ PFU/mL, followed by library preparation (Illumina Nextera XT kit) and sequencing (Illumina NextSeq 500/550 kit) with singleend reads of 150 bp (Illumina 150-cycle midoutput kit v2,) according to Illumina's recommendations. Machine output files (binary base call [BCL]) were converted to FASTQ files using the bcl2fastq/2.20.0 program.

Most bioinformatic analyses were performed using Geneious Prime v2021.0.3 and its plugins (Biomatters). The reads were trimmed (Geneious Prime BBDuk plugin) with default parameters. Sequencing of PASA16 yielded 1,651,174 reads of 150 bp in size. Bacterial sequences were removed by map-to-reference on the *P. aeruginosa* PA14 genome sequence followed by *de novo* assembly of the remaining reads with the SPAdes plugin of Geneious Prime with default parameters. The resulting contigs were reassembled with the Geneious Prime assembler with the highest sensitivity to produce one major contig of ~60 kb, which was fine-tuned by 10 iterative cycles of map-to-reference of the trimmed reads and consensus generation. The average coverage was 3,580.1× with a standard deviation (SD) of 351.2.

The PASA16 genome is 66,127 bp long with a GC content of 55.6% and contains 90 coding DNA sequences (CDS). Its terminal repeats and analysis of the alignment of

Editor John J. Dennehy, Queens College CUNY Copyright © 2022 Alkalay-Oren et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

Address correspondence to Ronen Hazan, ronenh@ekmd.huji.ac.il.

The authors declare no conflict of interest.

Received 4 February 2022 Accepted 22 February 2022 Published 8 March 2022




FIG 1 A TEM visualization of the phage PASA16 with P. aeruginosa PA14.

de- and reassembled genomes reveal that the PASA16 genome topology is either circular or circularly permuted (8). The taxonomy of PASA16, as determined by GenBank, is *Duplodnaviria, Heunggongvirae, Uroviricota, Caudoviricetes, Caudovirales, Myoviridae*, and *Pbunavirus*. Annotation with RAST (9) revealed that most PASA16 genes encode phage-related or hypothetical proteins. One notable gene is a lytic enzyme gene (GenBank protein accession number QOI69201.1) coding a putative lysozyme-like endolysin. This gene increases the possibility of the phage having high lytic abilities against the target bacteria (10) and perhaps contributed to its success in phage therapy treatments. As a candidate for phage therapy, the phage sequence was scanned for virulence factors using ABRicate v1.0.1 (T. Seemann, https://github.com/tseemann/abricate) against all its databases with its default parameters. No virulence factors or resistance genes were identified, and therefore the phage was deemed safe for use in phage therapy treatments.

Data availability. The sequence of the annotated genome of PASA16 can be found in GenBank (accession number MT933737.1), and the raw data are available under NIH BioSample database project PRJNA706131, "The Israeli Phage Bank (IPB)," BioSample number SAMN25300365, and Sequence Read Archive (SRA) number SRX13974252.

ACKNOWLEDGMENTS

We thank the Core Research Facility team of the Hebrew University, Ein Kerem Campus, Abed Nasereddin, and Idit Shiff for the deep sequencing and Eduardo Berenshtein for the TEM microscopy.

The "United States-Israel Binational Science Foundation (BSF)" grant 2017123, the Israel Science Foundation (ISF-IPMP) grant ISF_1349/2020, and the Rosetrees Trust grant A2232 provided funding for the project.

REFERENCES

- Lister PD, Wolter DJ, Hanson ND. 2009. Antibacterial-resistant *Pseudomonas aeruginosa*: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 22:582–610. https:// doi.org/10.1128/CMR.00040-09.
- Moradali MF, Ghods S, Rehm BH. 2017. Pseudomonas aeruginosa lifestyle: a paradigm for adaptation, survival, and persistence. Front Cell Infect Microbiol 7:39. https://doi.org/10.3389/fcimb.2017.00039.
- 3. Behzadi P, Baráth Z, Gajdács M. 2021. It's not easy being green: a narrative

review on the microbiology, virulence and therapeutic prospects of multidrug-resistant *Pseudomonas aeruginosa*. Antibiotics 10:42. https://doi .org/10.3390/antibiotics10010042.

- Centers for Disease Control and Prevention. 2019. Antibiotic resistance threats in the United States, 2019. U.S. Department of Health and Human Services, CDC, Atlanta, GA. https://www.cdc.gov/drugresistance/pdf/threats -report/2019-ar-threats-report-508.pdf.
- 5. Khatami A, Lin RC, Petrovic-Fabijan A, Alkalay-Oren S, Almuzam S, Britton

PN, Brownstein MJ, Dao Q, Fackler J, Hazan R, Horne BA, Nir-Paz R, Iredell JR. 2021. Bacterial lysis, autophagy and innate immune responses during adjunctive phage therapy in a child. EMBO Mol Med 13:e13936. https://doi.org/10.15252/emmm.202113936.

- Khalifa L, Brosh Y, Gelman D, Coppenhagen-Glazer S, Beyth S, Poradosu-Cohen R, Que YA, Beyth N, Hazan R. 2015. Targeting *Enterococcus faecalis* biofilms with phage therapy. Appl Environ Microbiol 81:2696–2705. https://doi.org/10.1128/AEM.00096-15.
- Alkalay-Oren S, Gold N, Khalifa L, Yerushalmy O, Coppenhagen-Glazer S, Nir-Paz R, Hazan R. 2021. Complete genome sequences of two *Enterococcus faecalis* bacteriophages, EFGrKN and EFGrNG, targeted to phage therapy. Microbiol Resour Announc 10:16. https://doi.org/10.1128/MRA.00126-21.
- 8. Grossi GF, Macchiato MF, Gialanella G. 1983. Circular permutation analysis

of phage T4 DNA by electron microscopy. Z Naturforsch C Biosci 38: 294–296. https://doi.org/10.1515/znc-1983-3-422.

- Brettin T, Davis JJ, Disz T, Edwards RA, Gerdes S, Olsen GJ, Olson R, Overbeek R, Parrello B, Pusch GD, Shukla M, Thomason JA, III, Stevens R, Vonstein V, Wattam AR, Xia F. 2015. RASTtk: a modular and extensible implementation of the RAST algorithm for building custom annotation pipelines and annotating batches of genomes. Sci Rep 5:8365. https://doi .org/10.1038/srep08365.
- Vasina DV, Antonova NP, Grigoriev IV, Yakimakha VS, Lendel AM, Nikiforova MA, Pochtovyi AA, Remizov TA, Usachev EV, Shevlyagina NV, Zhukhovitsky VG, Fursov MV, Potapov VD, Vorobev AM, Aleshkin AV, Laishevtsev AI, Makarov VV, Yudin SM, Tkachuk AP, Gushchin VA. 2021. Discovering the potentials of four phage endolysins to combat Gram-negative infections. Front Microbiol 12:748718. https://doi.org/10.3389/fmicb.2021.748718.